Appendiceal Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: APP003 MIFTS: 40	Appendiceal Neoplasm Categories: Cancer diseases, Gastrointestinal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Appendiceal Neoplasm

MalaCards integrated aliases for Appendiceal Neoplasm:

Name: Appendiceal Neoplasm ¹¹ ¹⁴ ¹⁶

Malignant Neoplasm of Appendix Vermiformis ³³

Malignant Tumour of Appendix ³³

Appendiceal Neoplasms ⁵³

Neoplasm of Appendix ¹¹

Appendiceal Cancer ³³

Appendix Neoplasm ¹¹

Appendix Cancer ³³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of digestive organs

Malignant neoplasms of intestine

Malignant neoplasms of appendix

Malignant neoplasms of appendix, unspecified

Other specified malignant neoplasms of appendix

External Ids:

Disease Ontology ¹¹ DOID:11240

MeSH ⁴³ D001063

NCIt ⁴⁹ C4434

SNOMED-CT ⁶⁸ 126846004

EFO ¹⁶ EFO_0003880

ICD11 ³³ 1892026854 1892026854/other 1892026854/unspecified

UMLS ⁷¹ C0003614

Sources

Summaries for Appendiceal Neoplasm

MalaCards based summary: Appendiceal Neoplasm, also known as malignant neoplasm of appendix vermiformis, is related to appendix cancer and pseudomyxoma peritonei. An important gene associated with Appendiceal Neoplasm is SATB2 (SATB Homeobox 2), and among its related pathways/superpathways are Cell surface interactions at the vascular wall and CCR3 Pathway in Eosinophils. The drugs Durvalumab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include appendix, small intestine and colon, and related phenotypes are Reduced mammosphere formation and neoplasm

Sources

Related Diseases for Appendiceal Neoplasm

Diseases related to Appendiceal Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 396)

#	Related Disease	Score	Top Affiliating Genes
1	appendix cancer	30.5	SATB2 PEX19 KRT7 KRAS HRAS GNAS
2	pseudomyxoma peritonei	29.9	KRT7 KRAS GNAS CEACAM5 CDX2
3	anal canal carcinoma	29.8	KRT7 CEACAM5 CDX2
4	cystadenoma	29.8	KRT7 GNAS CHGA CEACAM5
5	intestinal obstruction	29.8	KRT7 CEACAM5 CDX2
6	cystadenocarcinoma	29.7	KRT7 KRAS CEACAM5
7	krukenberg carcinoma	29.7	SATB2 KRT7 CEACAM5 CDX2
8	tubular adenocarcinoma	29.7	KRT7 CHGA CEACAM5 CDX2
9	rectum cancer	29.4	KRAS HRAS CEACAM5
10	ovarian cystadenocarcinoma	29.2	KRAS HRAS GNAS CEACAM5
11	colon adenocarcinoma	29.2	KRAS HRAS GNAS CEACAM5
12	intestinal benign neoplasm	29.2	KRAS HRAS CEACAM5 CDX2
13	rectal benign neoplasm	28.9	KRT7 KRAS HRAS CEACAM5 CDX2
14	mucinous adenocarcinoma	28.9	KRT7 KRAS HRAS GNAS CEACAM5 CDX2
15	anus cancer	28.8	KRT7 KRAS HRAS CEACAM5 CDX2
16	colonic benign neoplasm	28.8	KRT7 KRAS HRAS CEACAM5 CDX2
17	adenoma	28.8	KRT7 KRAS HRAS GNAS CHGA CDX2
18	colorectal adenocarcinoma	28.7	SATB2 KRT7 KRAS HRAS CEACAM5 CDX2
19	villous adenoma	28.7	KRT7 KRAS HRAS GNAS CEACAM5 CDX2
20	ovary adenocarcinoma	28.6	KRT7 KRAS HRAS GNAS CEACAM5 CDX2
21	lynch syndrome	28.5	KRT7 KRAS HRAS GNAS CEACAM5 CDX2
22	adenocarcinoma	28.5	KRT7 KRAS HRAS CHGA CEACAM5 CDX2
23	mucinous cystadenocarcinoma	28.4	MIR4328 KRT7 KRAS HRAS CEACAM5 CDX2
24	signet ring cell adenocarcinoma	28.4	KRT7 KRAS HRAS CHGA CEACAM5 CDX2
25	appendix adenocarcinoma	27.6	SATB2 PEX19 KRT7 KRAS HRAS GNAS
26	appendix carcinoid tumor	11.1
27	appendicitis	10.4
28	ovarian cyst	10.3	GNAS CEACAM5
29	mucinous cystadenocarcinoma of pancreas	10.3	SATB2 CEACAM5
30	parosteal osteosarcoma	10.3	SATB2 GNAS
31	peripheral osteosarcoma	10.3	SATB2 GNAS
32	atypical polypoid adenomyoma	10.3	SATB2 CDX2
33	laryngeal mucoepidermoid carcinoma	10.2	CEACAM5 CDX2
34	thymus adenocarcinoma	10.2	CEACAM5 CDX2
35	ovarian cystadenoma	10.2	KRT7 CEACAM5
36	carcinoid syndrome	10.2
37	goblet cell carcinoid	10.2
38	gallbladder carcinoma in situ	10.2	CEACAM5 CDX2
39	leukoplakia of penis	10.2	KRT7 CEACAM5
40	trachea carcinoma	10.2	KRT7 CEACAM5
41	urethral villous adenoma	10.2	KRT7 CEACAM5
42	bladder signet ring cell adenocarcinoma	10.2	KRT7 CDX2
43	pancreatic serous cystadenocarcinoma	10.2	KRT7 CEACAM5
44	aggressive digital papillary adenocarcinoma	10.2	KRT7 CEACAM5
45	cutaneous mucoepidermoid carcinoma	10.2	KRT7 CEACAM5
46	malignant epithelial mesothelioma	10.2	KRT7 CEACAM5
47	malignant spiradenoma	10.2	KRT7 CEACAM5
48	spiradenoma	10.2	KRT7 CEACAM5
49	eccrine porocarcinoma	10.2	KRT7 CEACAM5
50	adenosquamous bile duct carcinoma	10.2	KRT7 CEACAM5

Graphical network of the top 20 diseases related to Appendiceal Neoplasm:

Sources

Symptoms & Phenotypes for Appendiceal Neoplasm

GenomeRNAi Phenotypes related to Appendiceal Neoplasm according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.02	CHGA GNAS HRAS KRAS KRT7

MGI Mouse Phenotypes related to Appendiceal Neoplasm:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.55	CDX2 CEACAM5 GNAS HRAS KRAS
2	endocrine/exocrine gland	MP:0005379	9.5	CDX2 CEACAM5 CHGA GNAS HRAS KRAS
3	digestive/alimentary	MP:0005381	9.1	CDX2 CEACAM5 GNAS HRAS KRAS SATB2

Sources

Drugs & Therapeutics for Appendiceal Neoplasm

Drugs for Appendiceal Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Durvalumab

Approved, Investigational

Phase 1, Phase 2

1428935-60-7

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

50-18-0, 6055-19-2

2907

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Mitomycin

Approved

Phase 2

50-07-7

5746

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Cetuximab

Approved

Phase 1, Phase 2

205923-56-4

Floxuridine

Approved

Phase 2

50-91-9

5790

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Amoxicillin

Approved, Vet_approved

Phase 2

26787-78-0

33613

Carbamide peroxide

Approved

Phase 2

124-43-6

Dexlansoprazole

Approved, Investigational

Phase 2

138530-94-6

9578005

Lansoprazole

Approved, Investigational

Phase 2

103577-45-3

3883

Clarithromycin

Approved

Phase 2

81103-11-9

84029

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Nintedanib

Approved

Phase 2

656247-17-5

135423438 9809715

Irinotecan

Approved, Investigational

Phase 2

97682-44-5, 100286-90-6

60838

Nivolumab

Approved

Phase 2

946414-94-4

Ipilimumab

Approved

Phase 2

477202-00-9

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Exatecan

Investigational

Phase 1, Phase 2

171335-80-1

18546929 151115

Angiogenesis Inhibitors

Phase 2

Albumin-Bound Paclitaxel

Phase 2

Antimitotic Agents

Phase 2

Tubulin Modulators

Phase 2

Alkylating Agents

Phase 2

Antineoplastic Agents, Alkylating

Phase 2

Immunosuppressive Agents

Phase 2

Immunologic Factors

Phase 2

Vitamins

Phase 2

Folate

Phase 2

Vitamin B9

Phase 2

Trace Elements

Phase 2

Vitamin B Complex

Phase 2

Antimetabolites

Phase 2

Antidotes

Phase 2

Micronutrients

Phase 2

Protective Agents

Phase 2

Cola

Phase 2

Antibiotics, Antitubercular

Phase 2

Anti-Ulcer Agents

Phase 2

Anti-Bacterial Agents

Phase 2

Anti-Infective Agents

Phase 2

Antacids

Phase 2

Proton Pump Inhibitors

Phase 2

Cytochrome P-450 Enzyme Inhibitors

Phase 2

Gastrointestinal Agents

Phase 2

Cytochrome P-450 CYP3A Inhibitors

Phase 2

Protein Kinase Inhibitors

Phase 2

Interventional clinical trials:

(show all 37)

#	Name	Status	NCT ID	Phase	Drugs
1	Repetitive Electrostatic Pressurised Intraperitoneal Aerosol Chemotherapy With Oxaliplatin (ePIPAC-OX) as a Palliative Monotherapy for Isolated Unresectable Colorectal Peritoneal Metastases: Protocol of a Multicentre, Open-label, Single-arm, Phase II Study (CRC-PIPAC)	Completed	NCT03246321	Phase 2
2	Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C	Completed	NCT02040142	Phase 2	Mitomycin C
3	A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies	Completed	NCT02963831	Phase 1, Phase 2	Durvalumab
4	Phase II Trial of Adjuvant Thalidomide Following Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis or Adenomucinosis From Colorectal/Appendiceal Cancer	Completed	NCT00310076	Phase 2	thalidomide
5	Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Ovarian, or Other Gynecologic Primary Cancer	Recruiting	NCT05185947	Phase 2	Paclitaxel;Nilotinib
6	Phase II Single-Blind Randomized Trial Comparing Morbidity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis	Recruiting	NCT03073694	Phase 2	Mitomycin c;Melphalan
7	A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors	Recruiting	NCT04902872	Phase 1, Phase 2	CBX-12
8	Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	Recruiting	NCT04907643	Phase 2
9	A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation	Recruiting	NCT05194995	Phase 1, Phase 2	JAB-21822;Cetuximab
10	ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multi-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis	Recruiting	NCT01815359	Phase 2	HIPEC with Mitomycin-C;EPIC with FUDR and Leucovorin
11	Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial	Recruiting	NCT05472948	Phase 2	Surufatinib
12	Clinical Trial to Define the Effect of Perioperative H. Pylori Eradication With Antibiotic Treatment on Long Term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy	Active, not recruiting	NCT02387203	Phase 2	PrevPac (Prevacid, Amoxicillin, Clarithromycin)
13	LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma	Terminated	NCT03287947	Phase 2	nintedanib
14	A Phase II Study of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors	Terminated	NCT03693846	Phase 2	Nivolumab;Ipilimumab
15	Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery With Intraperitoneal Chemohyperthermia Using Oxaliplatin Plus Irinotecan	Terminated	NCT00180960	Phase 2	Oxaliplatin and irinotecan
16	Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer	Completed	NCT02833753	Phase 1	Oxaliplatin
17	Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)	Recruiting	NCT04329494	Phase 1	Cisplatin;Doxorubicin;Fluorouracil;Irinotecan;Leucovorin;Mitomycin;Oxaliplatin
18	Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies	Recruiting	NCT04847063	Phase 1	Mitomycin C;Cisplatin;Doxorubicin;Oxaliplatin;5-Fluorouracil;Sodium Thiosulfate
19	Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study	Not yet recruiting	NCT05277766	Phase 1	PIPAC with Nal-IRI
20	Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous mFOLFIRI for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer	Terminated	NCT04158349	Phase 1	Oxaliplatin;mFOLFIRI
21	Selective Rather Than Routine Histopathological Examination Following Appendectomy and Cholecystectomy; the FANCY Study.	Unknown status	NCT03510923
22	Multicenter, International Online Documentation of Indications and Results of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC Und PITAC) for Treating Malignant Peritoneal and Pleural Diseases	Unknown status	NCT03210298
23	A Survey of the Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients	Completed	NCT02374411
24	Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the Appendix: An International Multicenter Study	Completed	NCT03852693
25	Trial of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Primary Peritoneal Cancers and Secondary Peritoneal Cancers From Stomach, Colorectal, Appendiceal, and/or Gynecological Origins	Completed	NCT03604653		Mitomycin c;CDDP 50;CDDP 75;Doxorubicin
26	GI 1549: PROGRAMS TO SUPPORT YOU DURING CHEMOTHERAPY (PRO-YOU) A Randomized Controlled Pilot Study of Yoga Compared to an Attention Control in Patients Receiving Chemotherapy	Completed	NCT02489422
27	Surgical Outcome and Predictors of Overall Survival of Stage I-III Appendiceal Adenocarcinoma; a National Cancer Database Analysis	Completed	NCT05452382
28	A Cohort Study of the Gastrointestinal Microbiome in Appendiceal Cancer With Peritoneal Spread	Recruiting	NCT02599116
29	A Phase II Trial to Analyze Clinical and Pharmacological Properties for Severe Neutropenia After Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy Using Mitomycin-C	Recruiting	NCT05513183
30	Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Recurrence in Patients With High-risk Colorectal and Appendiceal Neoplasms : a Pilot Study	Recruiting	NCT05623787
31	5-hydroxymethylation Signatures in Plasma Circulating Cell-free DNA as Markers for Tumor Burden and Recurrence in Appendiceal and Colorectal Peritoneal Metastasis	Recruiting	NCT04157322
32	The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)	Recruiting	NCT04028479		Systemic Treatment (T)
33	The PANO Trial: Perioperative Exercise and Nutrition Optimisation Prehabilitation in Cancer Patients With Peritoneal Malignancy	Recruiting	NCT05305820
34	A Pragmatic, Single-Arm Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy	Recruiting	NCT04526886
35	The Prevalence of Appendiceal Tumours in Patients Presenting With a Periappendicular Abscess - A Nationwide Prospective Cohort Study	Not yet recruiting	NCT04634448
36	Justification of Incidental Appendectomy With Respect to Pathohistological Findings	Not yet recruiting	NCT05202600
37	Characterisation of Appendiceal Cancer by Genomic and Transcriptomic Analysis and Correlation With Clinical Outcomes	Not yet recruiting	NCT05364788

Search NIH Clinical Center for Appendiceal Neoplasm

Sources

Genetic Tests for Appendiceal Neoplasm

Sources

Anatomical Context for Appendiceal Neoplasm

Organs/tissues related to Appendiceal Neoplasm:

MalaCards : Appendix, Small Intestine, Colon, Lymph Node, Ovary, T Cells, Liver

Sources

Publications for Appendiceal Neoplasm

Articles related to Appendiceal Neoplasm:

(show top 50) (show all 593)

#	Title	Authors	PMID	Year
1	Incomplete cytoreduction with peritoneal metastases from appendiceal mucinous neoplasms. ⁶²	Sugarbaker PH...Chang D	36102369	2022
2	Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study. ⁶²	Turner KM...Patel SH	36258061	2022
3	Overall Survival after Systemic Chemotherapy in Patients with High-Grade Appendiceal Cancer Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). ⁶²	Nagarajan B...Sundaramurthi S	36344797	2022
4	The appendix "mucocoele" misnomer: radiological terminology of "likely appendix mucinous neoplasm" better reflects pathology findings. ⁶²	Bhagwanani A...Moran BJ	36411089	2022
5	Beware the distended appendix: technical adaptations to an appendicectomy when an appendiceal neoplasm is suspected. ⁶²	Arambepola D...Charalampakis V	36454069	2022
6	An Ex Vivo Organotypic Culture Platform for Functional Interrogation of Human Appendiceal Cancer Reveals a Prominent and Heterogenous Immunological Landscape. ⁶²	Weitz J...Lowy AM	36067351	2022
7	Peristomal Necrosis Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Case Report. ⁶²	van Kessel CS...Young CJ	36417381	2022
8	Validation of a Nomogram to Predict Recurrence in Patients with Mucinous Neoplasms of the Appendix with Peritoneal Dissemination After Cytoreductive Surgery and HIPEC. ⁶²	Martin Roman L...Gonzalez Bayon L	35876926	2022
9	Retroperitoneal mass, a rare manifestation of mucinous adenocarcinoma of appendix: A case report. ⁶²	Salehipour M...Kiani S	36415704	2022
10	Inherited Cancer Susceptibility Gene Sequence Variations Among Patients With Appendix Cancer. ⁶²	Holowatyj AN...Horton C	36368039	2022
11	Appendiceal Goblet Cell Adenocarcinoma: A Historically Informed Reading of 6 Cases. ⁶²	Wang Y...Loeffler A	35142802	2022
12	ASO Author Reflections: CRS/HIPEC Cannot be Done-Now what? Systemic Chemotherapy in Mucinous Appendiceal Cancer. ⁶²	Baron E...Ledakis P	35644859	2022
13	Acute lower gastrointestinal bleeding due to low-grade mucinous neoplasm of appendix. ⁶²	Karatas M...Uslu A	33274692	2022
14	ASO Visual Abstract: Socioeconomic Barriers to CRS HIPEC for Appendiceal Cancer within a Regional Academic Hospital System. ⁶²	Rieser C...Hoehn R	35798897	2022
15	Clinicopathological spectrums and prognosis of primary appendiceal adenocarcinoma, goblet cell adenocarcinoma, and low-grade appendiceal mucinous neoplasms. ⁶²	Chen I...Liao X	36454563	2022
16	Socioeconomic Barriers to CRS HIPEC for Appendiceal Cancer within a Regional Academic Hospital System. ⁶²	Rieser C...Hoehn RS	35639293	2022
17	Systemic Chemotherapy for High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread After Unsuccessful CRS/HIPEC. ⁶²	Baron E...Ledakis P	35641710	2022
18	Diverticulitis and Diverticulosis of the Appendix: A Case Series. ⁶²	Lesi OK...Saad Abdalla Al-Zawi A	36447679	2022
19	Amyand's hernia: which oncologic risk can be hidden in the sac? ⁶²	Montali F...Costi R	36134747	2022
20	Incidental Appendiceal Tumors During Appendectomy: A Nineteen-Year Retrospective Review at a Municipal Hospital. ⁶²	Lieb DA...Mariadason J	36074007	2022
21	Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. ⁶²	Baron E...Ledakis P	36253240	2022
22	Primary Appendiceal Adenocarcinoma Masquerading as Acute Appendicitis: A Case Report. ⁶²	Young G...Figueroa R	36225475	2022
23	Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists. ⁶²	Klink AJ...Antoine R	36089643	2022
24	Is Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy Still Indicated in Patients With Extraperitoneal Disease? ⁶²	Beal EW...Cloyd JM	35525209	2022
25	Second-look Surgery for Appendiceal High Grade and Colorectal Cancers Following Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). ⁶²	Breakeit M...Morris DL	36099142	2022
26	Initial Experience of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Baltic Country Center. ⁶²	Rackauskas R...Strupas K	36233421	2022
27	An unusual case of appendicitis due to appendiceal neuroendocrine tumor in a patient: A case report. ⁶²	Gao T...Xu W	35837025	2022
28	Clinicopathological features of appendiceal goblet cell adenocarcinoma in Japan: a multicenter retrospective study. ⁶²	Shiota T...Study Group of Appendiceal Neoplasms from the Japan Society of Colorectal Cancer Research Group	35913635	2022
29	Signet-ring cell carcinoma of the appendix with ganglioneuromatosis: a case report. ⁶²	Sato A...Okazumi S	35927360	2022
30	Revisiting the necessity for routine appendectomies in mucinous neoplasms of the ovary: An evaluation of 460 mucinous ovarian tumors. ⁶²	Albloshi A...Fadare O	35439697	2022
31	Accidental discovery of appendiceal carcinoma during gynecological surgery: A case report. ⁶²	Wang L...Sun L	36158468	2022
32	Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches. ⁶²	Chang SC...Chen WT	35430126	2022
33	Cerebral Metastases in Appendiceal Cancer: Comprehensive Review and Report of Rare Medullary Carcinoma Histology. ⁶²	Mackel C...Stippler M	35929119	2022
34	Mucinous appendiceal neoplasms and pseudomyxoma peritonei: Morphological and clinical findings, differential diagnosis, and prognosis. ⁶²	Akay E...Karaman H	35900483	2022
35	Lymph node positive pseudomyxoma peritonei. ⁶²	Sugarbaker PH...Chang D	35941031	2022
36	Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience. ⁶²	Fung X...Mohamed F	35168851	2022
37	Bone metaplasia of the appendix presented with clinical and computed tomography signs of acute appendicitis managed with laparoscopic appendectomy. ⁶²	Janez J	35915527	2022
38	Prognostic Impact of Pathology, Cytoreduction, and Tumor Markers in Pseudomyxoma Peritonei. ⁶²	Lopes A...Ribeiro U	35123285	2022
39	Incidental Finding of Appendiceal Mucinous Neoplasm After Trauma: A Case Report. ⁶²	Odom R...Burns B	35836463	2022
40	ASO Author Reflections: If at First You Don't Succeed, Try, Try Again: Iterative CRS/HIPEC for Recurrent Mucinous Appendix Cancer. ⁶²	Lopez-Ramirez F...Sardi A	35015184	2022
41	Appendiceal Cancer in the National Cancer Database: Increasing Frequency, Decreasing Age, and Shifting Histology. ⁶²	Salazar MC...Schuster KM	35703801	2022
42	Survival and prognostic factors for postoperative primary appendiceal cancer: a retrospective cohort study based on the Surveillance, Epidemiology, and End Results database. ⁶²	Wang Y...Hu W	35837159	2022
43	After thirty years of experience with early postoperative intraperitoneal 5-fluorouracil now saying goodbye. ⁶²	Sugarbaker PH	35398760	2022
44	Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix. ⁶²	Lopez-Ramirez F...Sardi A	35133518	2022
45	Case series on high grade appendiceal cancer with peritoneal and liver carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). ⁶²	Roy SP...Morris DL	35398783	2022
46	A Canadian single-centre experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for abdominal malignancies. ⁶²	Nassabein R...Tehfe M	35580884	2022
47	The association between appendicitis severity and patient age with appendiceal neoplasm histology-a population-based study. ⁶²	Alajaaski J...Salminen P	35474547	2022
48	Incidental Findings of Appendiceal Diverticulitis Presenting as Acute Appendicitis. ⁶²	Souferi B...Davis JM	34937429	2022
49	Re: Tuberculosis, still the great mimicker: a rare case of disseminated tuberculosis masquerading as appendiceal cancer with peritoneal carcinomatosis. ⁶²	Yagnik VD...Gupta K	35434958	2022
50	A case report of appendiceal adenocarcinoma without gastrointestinal evidence mimicking primary ovarian cancer. ⁶²	Lin CW...Wu PY	35387517	2022

Sources

Genes for Appendiceal Neoplasm

Genes related to Appendiceal Neoplasm (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SATB2	SATB Homeobox 2	Protein Coding	6.22	DISEASES inferred ¹⁴
2	GNAS	GNAS Complex Locus	Protein Coding	6.13	DISEASES inferred ¹⁴
3	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	6.12	DISEASES inferred ¹⁴
4	CDX2	Caudal Type Homeobox 2	Protein Coding	6.07	DISEASES inferred ¹⁴
5	KRT7	Keratin 7	Protein Coding	5.75	DISEASES inferred ¹⁴
6	MIR4328	MicroRNA 4328	RNA Gene	5.64	DISEASES inferred ¹⁴
7	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	5.62	DISEASES inferred ¹⁴
8	PEX19	Peroxisomal Biogenesis Factor 19	Protein Coding	5.46	DISEASES inferred ¹⁴
9	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	5.45	DISEASES inferred ¹⁴
10	CHGA	Chromogranin A	Protein Coding	5.4	DISEASES inferred ¹⁴

Sources

Variations for Appendiceal Neoplasm

Sources

Expression for Appendiceal Neoplasm

Search GEO for disease gene expression data for Appendiceal Neoplasm.

Sources

Pathways for Appendiceal Neoplasm

Pathways related to Appendiceal Neoplasm according to GeneCards Suite gene sharing:

(show all 18)

#	Super pathways	Score	Top Affiliating Genes
1	Cell surface interactions at the vascular wall ⁶⁶ Show member pathways Fibronectin matrix formation ⁶⁶ PECAM1 interactions ⁶⁶ Tie2 Signaling ⁶⁶	11.87	KRAS HRAS CEACAM5
2	CCR3 Pathway in Eosinophils ⁶⁴ Show member pathways VEGF and S-1P Signaling ⁶⁴	11.71	KRAS HRAS GNAS
3	Thermogenesis ⁷⁴ Show member pathways mitochondrial L-carnitine shuttle ⁶¹	11.49	KRAS HRAS GNAS
4	Gastrin signaling pathway ⁷⁴	11.38	KRAS HRAS CHGA
5	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.18	KRAS HRAS GNAS
6	Envelope proteins and their potential roles in EDMD physiopathology ⁷⁴	11.13	KRAS HRAS
7	Regulation of Ras family activation ⁶¹ Show member pathways Activation of RAS in B cells ⁶⁶	11.07	KRAS HRAS
8	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities ⁷⁴	11.03	KRAS HRAS
9	Aryl hydrocarbon receptor pathway ⁷⁴	11.02	KRAS HRAS
10	Bisphosphonate Pathway, Pharmacodynamics ⁶⁰ Show member pathways RalA downstream regulated genes ⁷⁴	11	KRAS HRAS
11	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	10.97	KRAS HRAS
12	RAS processing ⁶⁶	10.94	KRAS HRAS
13	Gastrin-CREB signalling pathway via PKC and MAPK ⁶⁶ Show member pathways EGFR Transactivation by Gastrin ⁶⁶	10.93	KRAS HRAS
14	MNAR-PELP1 and Estrogen Receptor Interaction ⁶⁴	10.84	KRAS HRAS
15	CD209 (DC-SIGN) signaling ⁶⁶	10.76	HRAS KRAS
16	VEGFR2 mediated cell proliferation ⁶⁶	10.73	HRAS KRAS
17	Serotonin HTR1 group and FOS pathway ⁷⁴ Show member pathways Serotonin receptor 2 and ELK-SRF/GATA4 signaling ⁷⁴ Serotonin receptor 4/6/7 and NR3C signaling ⁷⁴	10.58	KRAS HRAS GNAS
18	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.4	KRAS HRAS